{"id":10378,"date":"2024-10-03T07:27:34","date_gmt":"2024-10-03T12:27:34","guid":{"rendered":"https:\/\/ibio.org\/?p=10378"},"modified":"2024-10-03T07:27:34","modified_gmt":"2024-10-03T12:27:34","slug":"eli-lilly-boosts-indianas-biotech-hub-with-4-5-billion-medicine-foundry-investment","status":"publish","type":"post","link":"https:\/\/ibio.org\/eli-lilly-boosts-indianas-biotech-hub-with-4-5-billion-medicine-foundry-investment\/","title":{"rendered":"Eli Lilly Boosts Indiana&#8217;s Biotech Hub with $4.5 Billion &#8216;Medicine Foundry&#8217; Investment"},"content":{"rendered":"<p class=\"whitespace-pre-wrap break-words\">Eli Lilly and Company, a leading pharmaceutical giant, has announced plans to invest $4.5 billion in a groundbreaking new facility aimed at revolutionizing drug production and accelerating the development of medicines for clinical trials. The announcement comes as Lilly continues to strengthen its position in the rapidly growing market for weight-loss and diabetes treatments.<\/p>\n<h2 class=\"font-600 text-xl font-bold\">The Lilly Medicine Foundry<\/h2>\n<p class=\"whitespace-pre-wrap break-words\">The new center, dubbed the &#8220;Lilly Medicine Foundry,&#8221; will be located in Lebanon, Indiana, as part of the LEAP Research and Innovation District. Set to open in late 2027, this state-of-the-art facility will combine advanced manufacturing capabilities with innovative drug development processes. The Medicine Foundry represents a unique approach in the pharmaceutical industry, merging research and manufacturing under one roof.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">Key features of the Lilly Medicine Foundry include:<\/p>\n<ul class=\"-mt-1 list-disc space-y-2 pl-8\">\n<li class=\"whitespace-normal break-words\">Focus on developing new manufacturing methods for medicines<\/li>\n<li class=\"whitespace-normal break-words\">Increased capacity for producing experimental drugs for clinical trials<\/li>\n<li class=\"whitespace-normal break-words\">Flexible design to accommodate various molecular therapies, including small molecules, biologics, and nucleic acid therapies<\/li>\n<li class=\"whitespace-normal break-words\">Potential to increase Lilly&#8217;s output by up to 400%, according to CEO David Ricks<\/li>\n<\/ul>\n<h2 class=\"font-600 text-xl font-bold\">Expanding Workforce and Economic Impact<\/h2>\n<p class=\"whitespace-pre-wrap break-words\">The investment is expected to create 400 new full-time jobs for highly skilled workers, including engineers, scientists, operations personnel, and lab technicians. This expansion aligns with Lilly&#8217;s ongoing commitment to growth in Indiana, where the company has deep historical roots.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">Indiana Governor Eric J. Holcomb praised the investment, stating, &#8220;Lilly&#8217;s continued investment in Indiana solidifies our state&#8217;s role as a hub for cutting-edge science and technology.&#8221;<\/p>\n<h2 class=\"font-600 text-xl font-bold\">Meeting Growing Demand<\/h2>\n<p class=\"whitespace-pre-wrap break-words\">Lilly&#8217;s investment comes at a crucial time as the company faces surging demand for its popular weight-loss and diabetes drugs, Zepbound and Mounjaro. The GLP-1 agonist market, in which Lilly is a leader alongside Danish competitor Novo Nordisk, is projected to reach $150 billion by the early 2030s.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">The new facility will help Lilly address supply challenges and support the development of its robust pipeline, which includes promising obesity and neurological disease treatments such as:<\/p>\n<ul class=\"-mt-1 list-disc space-y-2 pl-8\">\n<li class=\"whitespace-normal break-words\">Orforglipron, an oral drug candidate<\/li>\n<li class=\"whitespace-normal break-words\">Retatrutide, an injectable drug candidate in late-stage studies<\/li>\n<\/ul>\n<h2 class=\"font-600 text-xl font-bold\">Part of a Larger Investment Strategy<\/h2>\n<p class=\"whitespace-pre-wrap break-words\">The Lilly Medicine Foundry is the latest in a series of significant investments by the company:<\/p>\n<ul class=\"-mt-1 list-disc space-y-2 pl-8\">\n<li class=\"whitespace-normal break-words\">May 2022: $2.1 billion for two manufacturing sites in Lebanon<\/li>\n<li class=\"whitespace-normal break-words\">April 2023: Additional $1.6 billion investment<\/li>\n<li class=\"whitespace-normal break-words\">May 2024: $5.3 billion commitment to enhance capacity for active pharmaceutical ingredients<\/li>\n<\/ul>\n<p class=\"whitespace-pre-wrap break-words\">With this new investment, Lilly&#8217;s total capital commitment in the United States since 2020 now exceeds $23 billion, underscoring the company&#8217;s dedication to innovation and growth in the pharmaceutical industry.<\/p>\n<p>This article was developed based on a<a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-announces-new-45-billion-site-lilly-medicine-foundry-drive#:~:text=The%20first%2Dever%20facility%20of,to%20more%20than%20%2413%20billion%20.\"> press release<\/a> issued by Eli Lilly and Company on October 2, 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company, a leading pharmaceutical giant, has announced plans to invest $4.5 billion in a groundbreaking new facility aimed at revolutionizing drug production and accelerating the development of medicines for clinical trials. The announcement comes as Lilly continues to strengthen its position in the rapidly growing market for weight-loss and diabetes treatments. The [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":10379,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[145],"tags":[653,654],"class_list":["post-10378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-news","tag-eli-lilly","tag-indiana"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=10378"}],"version-history":[{"count":1,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10378\/revisions"}],"predecessor-version":[{"id":10380,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10378\/revisions\/10380"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/10379"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=10378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=10378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=10378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}